{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:51Z","timestamp":1760188851724},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T00:00:00Z","timestamp":1153180800000},"content-version":"vor","delay-in-days":5677,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[1991,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fourteen patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) were treated with 10 \u00d7 10<jats:sup>6<\/jats:sup> U of nonrecombinant interferon alpha (IFN) intramuscularly (IM) daily for 3 days every 28 days. There were 11 men and 3 women, with ages ranging from 48 to 74 years. Patients had previously been treated with surgery (9 patients), radiotherapy (13 patients), or chemotherapy (8 patients). All patient had measurable disease by physical exam and radiologic evaluation and a performance status of \u2a7d2 (ECOG). Patients were treated for a minimum of 3 months and continued on therapy until disease progression. The dose and treatment schedule of IFN was well\u2010tolerated. Toxicities included low\u2010grade fever, mild anorexia, and malaise. Treatment was stopped in 1 patient due to the development of atrial fibrillation. One death occurred as a complication of aspiration pneumonia 2 weeks following the onset of therapy and was not felt to be related to IFN therapy. Of the 14 patients treated, there was 1 complete response (30+ months) of a base of tongue primary. Two patients had stabilization of disease (SD, 8 and 12 months). One patient had a mixed response with resolution of subcutaneous nodules. The remaining 10 patients died of progressive disease. Immunoogical assessment was performed on 8 patients. The 1 patient who has a complete response was noted to have markedly low pretreatment natural killer (NK) cell activity and subsequent sharp rise in activity after intial treatment. We conclude that low\u2010dose cyclic IFN is well\u2010tolerated in patients with recurrent SCCHN and has potential antitumor activity.<\/jats:p>","DOI":"10.1002\/hed.2880130103","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T21:40:38Z","timestamp":1172094038000},"page":"15-21","source":"Crossref","is-referenced-by-count":31,"title":["Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck"],"prefix":"10.1002","volume":"13","author":[{"given":"Daniel R.","family":"Vlock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Pelch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sigler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Colao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Rust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"70","article-title":"Head and neck cancer: chemotherapy concepts","volume":"15","author":"Al\u2010Sarraf M","year":"1988","journal-title":"Semin Oncol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00144263"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890090606"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.9.1410"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850801)56:3<432::AID-CNCR2820560304>3.0.CO;2-X"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(83)80247-5"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.7.1121"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198712000-00002"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/019459988609500203"},{"key":"e_1_2_1_11_2","first-page":"869","article-title":"Natural killer cell activity and head and neck cancer: a clinical assessment","volume":"77","author":"Schantz SP","year":"1986","journal-title":"JNCI"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860615)57:12<2295::AID-CNCR2820571211>3.0.CO;2-Q"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890090503"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0503(86)80303-4"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00458563"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1987.01860110073011"},{"key":"e_1_2_1_17_2","first-page":"103","article-title":"Biological approaches to cancer therapy","volume":"31","author":"Foon KA","year":"1987","journal-title":"Hamatol Bluttransfus"},{"key":"e_1_2_1_18_2","first-page":"68","article-title":"The immunologic treatment of cancer","volume":"38","author":"Lotze MT","year":"1988","journal-title":"CA"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1987.7.575"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/cdd.1985.2.91"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00410690"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/cdd.1985.2.53"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1985.3.6.813","article-title":"Treatment of nasopharyngeal carcinoma with human leukocyte interferon","volume":"3","author":"Connors JM","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_24_2","first-page":"308","volume-title":"Manual of clinical laboratory immunology","author":"Herberman RB","year":"1986"},{"key":"e_1_2_1_25_2","first-page":"274","volume-title":"Manual of clinical laboratory immunology","author":"Maluish AE","year":"1986"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1985.5.191"},{"key":"e_1_2_1_27_2","first-page":"528","article-title":"Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN\u2010alpha) in phase I\u2010II trials","volume":"2","author":"Ernstoff MS","year":"1983","journal-title":"J Biol Response Mod"},{"key":"e_1_2_1_28_2","first-page":"423","article-title":"2\u20105 A synthetase activity in patients with metastatic carcinoma and its reponse to interferon treatment","volume":"202","author":"Merritt JA","year":"1985","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1986.6.189"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111905"},{"key":"e_1_2_1_31_2","first-page":"1161","article-title":"Design of clinical trials with biological response modifiers","volume":"69","author":"Herberman RB","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841868709104360"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197906)43:6<2202::AID-CNCR2820430607>3.0.CO;2-J"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830801)52:3<399::AID-CNCR2820520303>3.0.CO;2-1"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.2880130103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.2880130103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T04:46:46Z","timestamp":1698036406000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.2880130103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991,1]]}},"alternative-id":["10.1002\/hed.2880130103"],"URL":"https:\/\/doi.org\/10.1002\/hed.2880130103","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,1]]}}}